Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen

C. Castagnola, E. P. Alessandrino, G. Pagnucco, P. Bernasconi, M. Lunghi, A. Colombo, E. Brusamolino, M. Bonfichi, A. Corso, M. Lazzarino, C. Bernasconi

Research output: Contribution to journalArticle

Abstract

Thirty-three patients with acute myeloid leukemia (AML), median age 36 years (range 19-59), treated with the MEC regimen as salvage therapy for refractory or relapsed disease were analyzed for long term outcome. Characteristics: 10 primary refractory, 9 early relapse (ie, remission l,000/mL and platelet >50,000/mL was 29 and 24 days respectively. Myelosuppression and infection were the major toxicities. Extrahematologic toxicity was mild or moderate, consisting mostly of nausea and vomiting, oral mucositis and transient liver or cardiac dysfunction. Multivariate analysis showed the type of resistance as the only factor affecting response: 79% CR rate in patients with a first CR lasting >6 months versus 20% in refractory AML and 33% in AML relapsed within 6 months (p

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
Publication statusPublished - 2000

Fingerprint

Mitoxantrone
Cytarabine
Etoposide
Acute Myeloid Leukemia
Refractory materials
Toxicity
Salvaging
Salvage Therapy
Stomatitis
Platelets
Liver
Nausea
Vomiting
Blood Platelets
Multivariate Analysis
Recurrence
Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen. / Castagnola, C.; Alessandrino, E. P.; Pagnucco, G.; Bernasconi, P.; Lunghi, M.; Colombo, A.; Brusamolino, E.; Bonfichi, M.; Corso, A.; Lazzarino, M.; Bernasconi, C.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Castagnola, C, Alessandrino, EP, Pagnucco, G, Bernasconi, P, Lunghi, M, Colombo, A, Brusamolino, E, Bonfichi, M, Corso, A, Lazzarino, M & Bernasconi, C 2000, 'Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen', Blood, vol. 96, no. 11 PART II.
Castagnola, C. ; Alessandrino, E. P. ; Pagnucco, G. ; Bernasconi, P. ; Lunghi, M. ; Colombo, A. ; Brusamolino, E. ; Bonfichi, M. ; Corso, A. ; Lazzarino, M. ; Bernasconi, C. / Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{6b44ce63782b40cdbc52e30f836bc957,
title = "Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen",
abstract = "Thirty-three patients with acute myeloid leukemia (AML), median age 36 years (range 19-59), treated with the MEC regimen as salvage therapy for refractory or relapsed disease were analyzed for long term outcome. Characteristics: 10 primary refractory, 9 early relapse (ie, remission l,000/mL and platelet >50,000/mL was 29 and 24 days respectively. Myelosuppression and infection were the major toxicities. Extrahematologic toxicity was mild or moderate, consisting mostly of nausea and vomiting, oral mucositis and transient liver or cardiac dysfunction. Multivariate analysis showed the type of resistance as the only factor affecting response: 79{\%} CR rate in patients with a first CR lasting >6 months versus 20{\%} in refractory AML and 33{\%} in AML relapsed within 6 months (p",
author = "C. Castagnola and Alessandrino, {E. P.} and G. Pagnucco and P. Bernasconi and M. Lunghi and A. Colombo and E. Brusamolino and M. Bonfichi and A. Corso and M. Lazzarino and C. Bernasconi",
year = "2000",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Outcome of patients with refractory/relapsed aml salvaged with the mec (mitoxantrone etoposide cytarabine) regimen

AU - Castagnola, C.

AU - Alessandrino, E. P.

AU - Pagnucco, G.

AU - Bernasconi, P.

AU - Lunghi, M.

AU - Colombo, A.

AU - Brusamolino, E.

AU - Bonfichi, M.

AU - Corso, A.

AU - Lazzarino, M.

AU - Bernasconi, C.

PY - 2000

Y1 - 2000

N2 - Thirty-three patients with acute myeloid leukemia (AML), median age 36 years (range 19-59), treated with the MEC regimen as salvage therapy for refractory or relapsed disease were analyzed for long term outcome. Characteristics: 10 primary refractory, 9 early relapse (ie, remission l,000/mL and platelet >50,000/mL was 29 and 24 days respectively. Myelosuppression and infection were the major toxicities. Extrahematologic toxicity was mild or moderate, consisting mostly of nausea and vomiting, oral mucositis and transient liver or cardiac dysfunction. Multivariate analysis showed the type of resistance as the only factor affecting response: 79% CR rate in patients with a first CR lasting >6 months versus 20% in refractory AML and 33% in AML relapsed within 6 months (p

AB - Thirty-three patients with acute myeloid leukemia (AML), median age 36 years (range 19-59), treated with the MEC regimen as salvage therapy for refractory or relapsed disease were analyzed for long term outcome. Characteristics: 10 primary refractory, 9 early relapse (ie, remission l,000/mL and platelet >50,000/mL was 29 and 24 days respectively. Myelosuppression and infection were the major toxicities. Extrahematologic toxicity was mild or moderate, consisting mostly of nausea and vomiting, oral mucositis and transient liver or cardiac dysfunction. Multivariate analysis showed the type of resistance as the only factor affecting response: 79% CR rate in patients with a first CR lasting >6 months versus 20% in refractory AML and 33% in AML relapsed within 6 months (p

UR - http://www.scopus.com/inward/record.url?scp=33748537358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748537358&partnerID=8YFLogxK

M3 - Article

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -